供应商 相关产品 基本信息 理化性质 应用领域 人参皂苷 RK3价格(试剂级) 常见问题列表
网站主页Cas数据库列表364779-15-7

364779-15-7

供应商 相关产品 基本信息 理化性质 应用领域 人参皂苷 RK3价格(试剂级) 常见问题列表

产品图片

基本信息

英文
Ginsenoside Rk3
中文
人参皂苷 RK3
英文名称
Ginsenoside Rk3
Ginsenoside Rk3 standard
β-D-Glucopyranoside, (3β,6α,12β)-3,12-dihydroxydammara-20,24-dien-6-yl
CAS
364779-15-7
中文名称
人参皂甙RK3
人参皂苷 RK3
人参皂苷RK3对照品
人参皂苷RK3(标准品)
人参皂苷RK3,R1=葡萄糖
人参皂苷RK3(人参皂甙RK3)
分子式
C36H60O8
分子量
620.87
MOL 文件
364779-15-7.mol

理化性质

外观性状
白色粉末,可溶于甲醇、乙醇、DMSO等有机溶剂,来源于人参。
沸点 
722.4±60.0 °C(Predicted)
密度 
1.20±0.1 g/cm3 (20 ºC 760 Torr)
酸度系数(pKa)
12.91±0.70(Predicted)

应用领域

用途1
用于含量测定/鉴定/药理实验等。
药理药效:可能有心血管、按肿瘤方面的活性
用途2
人参皂苷RK3存在于加工的田三七中,是常用的缺血性心脏疾病的复方制剂的主要成分。

人参皂苷 RK3价格(试剂级)

人参皂苷 RK3价格(试剂级)
更新日期产品编号产品名称CAS号包装价格
2023/01/06HY-N0906人参皂苷 RK3
Ginsenoside Rk3
364779-15-75mg2200元
2023/01/06HY-N0906人参皂苷 RK3
Ginsenoside Rk3
364779-15-710mg3700元
2023/01/06HY-N0906人参皂苷 RK3
Ginsenoside Rk3
364779-15-725mg6200元

常见问题列表

生物活性
Ginsenoside Rk3 存在于 Panax notoginseng 的根中。在 HepG2 细胞中 Ginsenoside Rk3 抑制 TNF-α 诱导的 NF-κB 转录活性, IC50 值为 14.24±1.30 μM。
靶点

NF-κB

14.24 μM (IC 50 , in HepG2 cells)

NF-κB

15.32 μM (IC 50 , in SK-Hep1 cell)


体外研究

Ginsenoside Rk3 exerts the strong activity inhibiting NF-κB in a dose-dependent manner. HepG2 cells are pre-treated with different ginsenosides at concentrations ranging from 0.01 to 10 μM for 1 h, and induced with TNF-α for 20 h. Ginsenoside Rk3 significantly inhibits TNF-α-induced NF-κB transcriptional activity, with an IC 50 of 14.24±1.30 μM. Ginsenoside Rk3 significantly inhibits TNF-α-induced NF-κB transcriptional activity, with an IC 50 of 15.32±0.29 μM in SK-Hep1 cells, consistent with the data from HepG2 cells. Consistent with the inhibition of NF-κB, Ginsenoside Rk3 inhibits the induction of IL8 , CXCL1 , iNOS , and ICAM1 mRNA significantly in a dose-dependent manner.


体内研究

The inhibitory effects of Ginsenoside Rk3 (Rk3) on tumor progression are studied in vivo using a H460 xenograft model in nude mice. Compared with the control group, a significant inhibition of tumor growth (volume) is observed in the Ginsenoside Rk3-treated group. Twenty-one days after treatment initiation, tumor growth is significantly inhibited by approximately 62.99% in the mice receiving 20 mg/kg Ginsenoside Rk3, similar to the inhibitory effect observed in the 20 mg/kg Gefitinib-treated group (57.21%). Compared with the control group, tumor growth is moderately inhibited in the mice receiving 10 and 5 mg/kg Ginsenoside Rk3, with inhibition rates of 32.54% and 11.84%, respectively.


供应商信息更多